The Molecular Diagnostics Market Will Register a CAGR of 5.6% during the Forecast Period to Reach $46.69 Billion by 2030, Says “Meticulous Research®.” Molecular diagnostics is the process of accessing a person’s health at the molecular level by analyzing specific genetic sequences. Advancements in molecular diagnostics have led to personalized healthcare, precision medicine, and predictive healthcare. During the COVID-19 pandemic, molecular diagnostics played a major role in providing accurate and faster diagnostic results. Molecular diagnostics comprises advanced products and technologies used by skilled professionals to improve patient health. Polymerase chain reaction (PCR) and microarray technology offer high throughput and more accurate tests. More recently, sequencing is an alternative molecular diagnostic technology that will be used widely in the coming years.
The factors such as the rising global geriatric population, the increasing prevalence of communicable and non-communicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures are driving the Molecular Diagnostics Market. Moreover, the growing scope in emerging countries, increasing focus on companion diagnostics and the rising popularity of direct-to-consumer (DTC) genetic testing is expected to create growth opportunities for the Molecular Diagnostics Market.
Here are the top 10 companies operating in the Molecular Diagnostics Market
F. Hoffmann-La Roche (Switzerland)
Founded in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche, commonly called Roche, is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company has two reportable business divisions, namely, Pharmaceuticals and Diagnostics. The Diagnostics division is further segmented into Core Lab, Molecular Lab, Point of Care, Diabetes Care, and Pathology Lab. The company offers molecular diagnostic products through the Molecular Lab segment.
Roche Molecular Diagnostics (RMD), a part of Roche headquartered in California, U.S., develops, manufactures, and supplies a wide range of molecular diagnostics products. The company’s global portfolio includes oncology, virology, microbiology, and blood screening tests for researchers, physicians, patients, hospitals, laboratories, and blood banks.
Roche has a presence in the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. The company has 23 manufacturing sites and 29 research and development sites.
Abbott Laboratories (U.S.)
Founded in 1888 and headquartered in Illinois, U.S., Abbott Laboratories is engaged in discovering, developing, manufacturing, and marketing a broad range of healthcare products. The company has four reportable business segments, namely, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers molecular diagnostics products through its Diagnostics business segment. The Diagnostic Products segment offers a broad line of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians’ offices, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic firms globally.
Abbott has a geographic presence across Germany, Japan, India, Switzerland, Russia, France, Brazil, Italy, the U.K., the U.S., the Netherlands, Colombia, Vietnam, and other countries. The company operates through its 90 manufacturing facilities across the globe, of which 24 are for diagnostic product manufacturing. The company has its R&D facilities in the U.S., China, Colombia, India, Singapore, Spain, and the U.K. Some of its subsidiaries are Abbott Diagnostics Medical Co., Ltd. (Japan), Alere Medical Private Limited (India), Murex Diagnostics, Inc. (U.S.), Abbott Point of Care Canada Limited (Canada), Abbott Diagnostics (Shanghai) Co., Ltd. (China), Abbott Diagnostics GmbH (Germany), Abbott Diagnostics Medical Co., Ltd. (Japan), and Abbott Rapid Diagnostics (PTY) LTD. (South Africa).
Hologic, Inc. (U.S.)
Founded in 1985 and headquartered in Massachusetts, U.S., Hologic, Inc. is engaged in developing, manufacturing, and supplying diagnostic products, medical imaging systems, and surgical products. The company operates through four business segments, namely, Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostic segment is further segmented into Cytology & Perinatal, Molecular Diagnostics, and Blood Screening. Both Molecular Diagnostics and Blood Screening segments offer molecular diagnostics products.
The Diagnostics segment’s R&D, administrative, and manufacturing operations take place in California, U.S. Some of the subsidiaries of Hologic are Hologic Asia Limited (Hong Kong), Hologic Deutschland GmbH (Germany), Tridaho LLC (U.S.), Gen-Probe Incorporated (U.S.), Diagenode Co., Ltd. (Japan).
Danaher Corporation (U.S.)
Founded in 1969 and headquartered in Washington DC, U.S., Danaher Corporation is a science and technology-based company. The company has three reportable business segments, namely, Life Sciences, Diagnostics, and Environmental & Applied Solutions. The company operates in the molecular diagnostics market through the Diagnostics segment. This segment offers a wide range of analytical instruments, reagents, consumables, software, and services to diagnose diseases and make crucial treatment decisions. The company offers its products to hospitals, physicians’ offices, reference laboratories, and other critical care settings.
Danaher has a geographic presence in over 60 countries, including the U.S., China, Denmark, Germany, Singapore, Sweden, Switzerland, and the U.K. The manufacturing facilities of the Diagnostics business segment are located in U.S., Europe, Asia, and Australia. Some of the subsidiaries of the company include Beckman Coulter Australia Pty Ltd, Beckman Coulter Canada LP, Beckman Coulter G.m.b.H. (Germany), Beckman Coulter India Private Limited, Beckman Coulter Nederland B.V., Beckman Coulter United Kingdom Limited, Cepheid AB (Sweden), Cepheid Europe SAS (France), Cepheid GmbH (Germany), Cepheid UK Ltd., Leica Biosystems Melbourne Pty Ltd (Australia), Radiometer K.K (Japan), Radiometer Medical Equipment (Shanghai) Co. Ltd. (China), and HomoCue AB (Sweden).
Illumina, Inc. (U.S.)
Founded in 1998 and headquartered in California, U.S., Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The company offers integrated sequencing and microarray systems, consumables, and analysis tools used by genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company operates in the molecular diagnostics market through the Core Illumina and GRAIL segments.
Illumina markets and distributes products across the U.S., Europe, Latin America, and Asia-Pacific. The company’s office, lab, and manufacturing facilities are located in the U.S., Singapore, and the U.K.. Some of its subsidiaries are BlueBee Holding BV (Netherlands), Conexio Genomics Pty Ltd. (Australia), Illumina Italy S.r.l., Illumina New Zealand Limited, Illumina (China) Scientific Co Ltd, Illumina Canada ULC, Illumina Singapore Pte. Ltd.
“Meticulous Research in its latest publication on Molecular Diagnostics Market has predicted the growth of 5.6% during the forecast year 2023-2030”
BioMérieux S.A. (France)
Founded in 1963 and headquartered in Marcy-l’Étoile, France, BioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions. The company operates globally via two business segments, namely, Clinical Applications and Industrial Applications. BioMérieux operates in the molecular diagnostics market through the Clinical Applications segment.
The Clinical Applications segment provides in vitro diagnostic solutions that help doctors and healthcare workers to determine the source of disease. This segment is further divided into three sub-segments, namely, Molecular Biology, Microbiology, and Immunoassays.
BioMérieux has a direct presence in 44 countries and a strong distribution network in more than 160 countries globally. The company generates more than 90% of its sales outside France. The company has overall 15 major production sites and 14 R&D centers.
Some of the subsidiaries of BioMérieux operating in the rapid diagnostics market include bioMérieux UK Ltd (U.K.), bioMérieux Inc (Canada), Cambridge bioMérieux Inc (U.S.) bioMérieux Japan Ltd (Japan), bioMérieuxBrazilS.A. (Brazil), bioMérieuxInc Egypt (Egypt), bioMérieuxCZs.r.o. (Chez Republic), bioMérieuxAustria GmbH (Austria), bioMérieuxespala S.A. (Spain), bioMérieuxAsia Pacific Pte. Ltd. (Singapore), bioMérieux China Ltd (China), and bioMérieux India Private Limited (India).
QIAGEN N.V. (Netherlands)
Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN N.V. provides sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company provides samples to insight solutions to transform biological materials into valuable molecular insights.
QIAGEN provides sample technologies that isolate and process DNA, RNA and proteins from any biological sample, such as blood or tissue. The company also provides assay technologies, digital insights, integrated software and cloud-based resources, and automated solutions to analyze and interpret small to large volumes of biological samples for seamless and cost-effective molecular testing workflows. QIAGEN operates in two major business segments, namely, Molecular Diagnostics and Life Sciences. The Molecular Diagnostics segment offers molecular diagnostics products.
QIAGEN markets its products in more than 130 countries through its subsidiaries. The company has great sales potential in Europe, Asia, America and Australia. The production and manufacturing facilities for consumable products are in Germany, the U.S., Spain, and China. The company has 35 subsidiaries in over 25 countries. Some of its subsidiaries include QIAGEN AG (Switzerland), QIAGEN China (Shanghai) Co. Ltd. (China), QIAGEN GmbH (Germany), QIAGEN Inc. (Canada), and QIAGEN K.K. (Japan).
Thermo Fisher Scientific Inc. (U.S.)
Founded in 2006 and headquartered in Massachusetts, U.S., Thermo Fisher offers a wide range of healthcare technologies, software and services. The company serves more than 400,000 pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research & academic institutions, and government firms, as well as environmental, industrial quality, and process control settings.
Thermo Fisher operates through four business segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company offers molecular diagnostics products through the Life Sciences Solutions and Specialty Diagnostics business segments. The Life Sciences Solutions business segment offers a wide range of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of infection and disease. The Specialty Diagnostics business segment offers a broad range of diagnostic test kits, reagents, instruments, culture media, and associated products used in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.
Thermo Fisher has a presence in approximately 50 countries. The company has major manufacturing and distribution facilities in the U.S., Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, and the U.K. Some of its subsidiaries are Thermo Fisher Scientific C.V. (Netherlands), ThermoSentron Canada Inc, Medical Diagnostics Systems, Inc. (U.S.), Fisher Scientific S.A.S (France), Fisher Scientific S.L (Spain), Thermo Fisher (Kandel) GmbH (Germany), Life Technologies Japan Ltd, Athena Diagnostics, Inc (U.S.), Scientific Products (Asia Pacific) Pte. Ltd. (Singapore), Thermo Fisher Scientific India Pvt Ltd (India), and Scientific Products (Shanghai) Pte. Ltd. (China)
Siemens Healthineers AG (Germany)
Founded in 1847 and headquartered in Erlangen, Germany, Siemens Healthineers AG is engaged in developing and selling various products with medical imaging applications, laboratory diagnostics, and point-of-care testing. The company also offers digital health platforms for various clinical specialties and laboratory diagnostic services globally. Siemens operates in four business segments, namely, Imaging, Diagnostics, Varian, and Advanced Therapies. The Diagnostic business segment offers products and services.
The company has a direct presence through its subsidiaries in more than 70 countries, including the U.S., Canada, Germany, the U.K., France, Italy, Spain, Denmark, Sweden, Switzerland, Belgium, India, China, Japan, Australia, New Zealand, the Republic of Korea, and other European countries. Furthermore, Siemens’ main production sites are in the U.S., Germany, and China. Some of its subsidiaries are Siemens Healthcare Diagnostics Products GmbH (Germany), Siemens Healthcare A/S (Denmark), Siemens Healthcare S.r.l. (Italy), Babson Diagnostics, Inc. (U.S.), and Siemens Healthineers Diagnostics (Shanghai) Co., Ltd. (China).
Seegene, Inc. (South Korea)
Founded in 2000 and headquartered in Seoul, South Korea, Seegene is a provider of multiplex molecular diagnostics products. The company develops instruments for molecular diagnostics through OEM partnerships. Furthermore, Seegene is engaged in developing its automation system, including DNA extraction, PCR reagent dispenser, auto electrophoresis, POCT, real-time PCR, and decapper.
The company’s high multiplex real-time PCR technologies include DPO Technology for multiple target amplification, TOCE Technology for multiple target detection, and MuDT Technology for multiple target real-time analysis. Seegene also produces molecular diagnostics (MDx) products that can detect multiple targets simultaneously. The company’s production systems are ISO9001:2015, ISO13485:2016, and MDSAP certified.
Seegene has a geographic presence across 60 countries, with 7 subsidiaries in North and South America, Europe, and the Middle East. Some of its subsidiaries are Seegene Germany GmbH (Germany), Seegene USA (U.S.), Seegene CANADA Inc. (Canada), Seegene MIDDLE EAST (UAE), Seegene Mexico (Mexico), Arrow Diagnostics S.r.l (Italy), and Seegene Brazil Diagnosticos LTDA (Brazil).
Amidst this crisis, Meticulous Research® is continuously assessing the impact of the COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/product/molecular-diagnostics-market-5375
Authoritative Research on the Molecular Diagnostics Market – Global Opportunity Analysis and Industry Forecast (2023-2030)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
- Impact of COVID-19 on the Molecular Diagnostics Market
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report of Molecular Diagnostics Market pages and learn more: https://www.meticulousresearch.com/download-sample-report/cp_id=5375